Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
Launched by ONCOHOST LTD. · Aug 13, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on helping doctors understand which patients with advanced stage IV lung cancer or melanoma might respond better to their cancer treatments. Researchers are developing a special tool, called an algorithm, that will help identify these patients by evaluating their body’s response during treatment. The goal is to personalize treatment plans to improve outcomes for those battling these serious cancers.
To participate in this trial, patients need to have stage IV non-small cell lung cancer or stage IV malignant melanoma, and they must have at least one measurable tumor that can be assessed through medical imaging. Participants should be generally healthy, meaning their blood counts and organ functions are within normal ranges. The study is currently looking for patients aged 65 to 74, and both men and women are welcome. If you decide to take part, you can expect to undergo regular evaluations to monitor your response to treatment and contribute to important research that could benefit others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Cancer patients with stage IV NSCLC or stage IV malignant melanoma
- • Patient must have at least one measurable lesion and the relevant images in order to enable assessment of response
- • ECOG PS - 0/1-2
- * Normal hematologic, renal and liver function:
- • 1. Absolute neutrophil count higher than 1500/mm3
- • 2. Platelets count higher than 100,000/mm3
- • 3. haemoglobin higher than 9 g/dL
- • 4. Creatinine concentration ≤1.4 mg/dL, or creatinine clearance higher than 40 mL/min
- • 5. Total bilirubin lower than 1.5 mg/dL, ALT and AST levels ≤ 3 times above the upper normal limit.
- Exclusion Criteria:
- • Concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of study drug
- • Generalized impairment or mental incompetence that would render the patient unable to understand his/her participation in the study.
About Oncohost Ltd.
OncoHost Ltd. is a pioneering biotechnology company focused on transforming cancer management through advanced precision medicine. By leveraging proprietary artificial intelligence and machine learning algorithms, OncoHost develops innovative solutions that enhance oncologists' ability to tailor treatment plans based on individual patient profiles. The company is dedicated to improving patient outcomes and quality of life by providing insights into tumor behavior and response to therapy, ultimately aiming to support more effective and personalized cancer care. Through its commitment to research and collaboration, OncoHost is at the forefront of revolutionizing the way cancer is diagnosed and treated.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jacksonville, Florida, United States
Miami, Florida, United States
Haifa, , Israel
Aberdeen, , United Kingdom
Germantown, Tennessee, United States
Aberdeen, , United Kingdom
Houston, Texas, United States
Torquay, , United Kingdom
Tel Aviv, , Israel
Ashkelon, , Israel
Tel Hashomer, , Israel
Kfar Saba, , Israel
Haifa, , Israel
Petah Tikva, , Israel
Afula, , Israel
Buffalo, New York, United States
Cheltenham, , United Kingdom
Heidelberg, , Germany
Sunderland, , United Kingdom
Stevenage, , United Kingdom
Tel Aviv, , Israel
Be'er Sheva, , Israel
Bradford, , United Kingdom
Reẖovot, , Israel
Bournemouth, , United Kingdom
Northwood, , United Kingdom
New Brunswick, New Jersey, United States
Be'er Ya'aqov, , Israel
Birmingham, Alabama, United States
Orlando, Florida, United States
Orlando, Florida, United States
Rolling Meadows, Illinois, United States
Cedar Rapids, Iowa, United States
Texarkana, Texas, United States
Tel Aviv, Hamerkaz, Israel
Jerusalem, , Israel
Tel Aviv, , Israel
Haverfordwest, , United Kingdom
Shrewsbury, , United Kingdom
South Shields, , United Kingdom
Swansea, , United Kingdom
Texarkana, Texas, United States
Gauting, , Germany
Seville, , Spain
Patients applied
Trial Officials
Alona Zer, MD
Principal Investigator
003 Rambam Medical Center
Michal Lotem, MD
Principal Investigator
001 Hadassah Medical Center
Jair Bar, MD
Principal Investigator
016 Sheba Medical Center
Maya Gottfried, MD
Principal Investigator
005 Meir Medical Center
Abed Agbaria, MD
Principal Investigator
004 Bnai Zion Medical Center
Ido Wolf, MD
Principal Investigator
002 Tel Aviv Sourasky Medical Center
Mahmud Abu-Amana, MD
Principal Investigator
007 Haemek Medical Center
Rivka Katsenelson, MD
Principal Investigator
008 Kaplan Medical Center
Alexander Yakobson, MD
Principal Investigator
009 Soroka Medical Center
Tatiana Harkovsky, MD
Principal Investigator
011 Barzilai Medical Center
Mor Moskovitz, MD
Principal Investigator
012 Rabin Medical Center
Elizabeta Dudnik, MD
Principal Investigator
013 Assuta Medical Center
Raya Leibowitz, MD
Principal Investigator
014 Shamir Medical Center
Adam Berger, MD
Principal Investigator
030 Rutgers Cancer Institute
Jose Lutzky, MD
Principal Investigator
032 University of Miami
Antony Magliocco, MD
Principal Investigator
015 Protean Biodiagnostics
Gillian Price, MD
Principal Investigator
020 Aberdeen Royal Infirmary
Helen Cheley
Principal Investigator
021 Swansea Bay UHB - Cancer Institute
Louise Medley, MD
Principal Investigator
022 Torbay and South Devon NHS foundation
Tom Geldart, MD
Principal Investigator
023 Royal Bournemouth General Hospital Dorset
Anirban Chatterjee, MD
Principal Investigator
024 The Shrewsbury and Telford Hospital
David Farrugia, MD
Principal Investigator
025 Cheltenham General Hospital
Andreas Polychronis, MD
Principal Investigator
026 Mount Vernon Cancer Centre
Andreas Polychronis, MD
Principal Investigator
027 Lister Hospital
Ari VanderWalde, MD
Principal Investigator
031 West Clinic
Davika Das, MD
Principal Investigator
033 VAHCS Birmingham
Alison Brewster, MD
Principal Investigator
051 Withybush Hospital Hawl Dda University Health Board
Adam Hassani
Principal Investigator
029 Sunderland Royal Hospital
Adam Hassani, MD
Principal Investigator
028 South Tyneside District
Andrew Conn, MD
Principal Investigator
050 Bradford Teaching Hospitals
Yanyan Lou, MD
Principal Investigator
034 Mayo Clinic
Igor Puzanov, MD
Principal Investigator
035 Roswell Park
Ernesto Bustinza, MD
Principal Investigator
153 Florida Cancer Specialists and Research Institute
Anita Sabichi, MD
Principal Investigator
036 Michael E Debakey VA Medical Center
Ronnie Shapira Frommer, MD
Principal Investigator
017 Sheba Medical Center
Ina Koch, PhD
Principal Investigator
040 Asklepios Klinik Gauting GmbH
Petros Christopoulos, MD
Principal Investigator
041 Thoraxklinik-Heidelberg gGmbH
Marina Messinger, MD
Principal Investigator
150 Northwest Community Healthcare
Sunil Patel, MD
Principal Investigator
151 CHRISTUS St. Michael Health System
William P Fusselman, MD
Principal Investigator
152 Physicians Clinic of Iowa
David Vecente, MD
Principal Investigator
044 Hospital Universitario Virgen Macarena
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials